<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967573</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-175R</org_study_id>
    <nct_id>NCT04967573</nct_id>
  </id_info>
  <brief_title>Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis</brief_title>
  <official_title>Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis (IDENT): a Prospective, Multicenter, Single-blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of anticoagulant treatment is not established for patients with acute&#xD;
      symptomatic isolated distal deep vein thrombosis (IDDVT). The latest Antithrombotic Therapy&#xD;
      for VTE Disease Guideline suggested using the same anticoagulation as for patients with acute&#xD;
      proximal DVT in patients with acute IDDVT. However, a single-center retrospective cohort&#xD;
      study found therapeutic anticoagulation was associated with an increase risk of bleeding.&#xD;
      Thus, this study aimed to assess the short-term risk of recurrent venous thrombotic events&#xD;
      and bleeding events in patients with a first acute symptomatic IDDVT of the leg treated with&#xD;
      prophylactic or therapeutic anticoagulant therapy with rivaroxaban.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">September 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrent venous thromboembolism</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrent venous thromboembolism includes extension of distal DVT to proximal deep veins, new contralateral proximal DVT and pulmonary embolism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of major bleeding events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with residual vein occlusion</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Prophylactic Anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10 mg od for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban 20 mg od for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 20 mg or 10 mg for 3 months</description>
    <arm_group_label>Prophylactic Anticoagulation</arm_group_label>
    <arm_group_label>Therapeutic Anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All outpatients with first, acute (within 2 weeks), symptomatic, objectively confirmed&#xD;
             distal DVT&#xD;
&#xD;
          -  Compliance to the scheduled follow up plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years or &gt; 90 years&#xD;
&#xD;
          -  Any absolute contraindication to anticoagulant treatment&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Serum creatinine &gt; 180 mmol/L or creatinine clearance â‰¤30 ml/min&#xD;
&#xD;
          -  Liver disease associated with coagulopathy and high risk of bleeding&#xD;
&#xD;
          -  Clinically suspected or confirmed pulmonary embolism&#xD;
&#xD;
          -  Ipsilateral or contralateral proximal DVT&#xD;
&#xD;
          -  Any indication for long-term anticoagulant treatment&#xD;
&#xD;
          -  Inability or refusal to provide informed consent&#xD;
&#xD;
          -  Enrolled in another clinical trial simultaneously&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenyu Shi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiguo Fu, PhD</last_name>
    <phone>17612117633</phone>
    <email>fu.weiguo@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huadong Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan Zhang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieqi Mao, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Wusong Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yucheng Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Shi, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

